UNBS5162 inhibits colon cancer growth via suppression of PI3K/Akt signaling pathway

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Colon cancer is a leading cause of cancer mortality globally.
• The precise mechanisms driving colon cancer progression are not fully understood.
• Identifying novel therapeutic targets is crucial for effective colon cancer treatment.

Purpose of the Study:

• To investigate the therapeutic potential of UNBS5162 in colon cancer.
• To elucidate the molecular mechanisms underlying UNBS5162's anti-cancer effects.
• To evaluate UNBS5162's impact on colon cancer cell proliferation, migration, invasion, and apoptosis.

Main Methods:

• Cell proliferation was assessed using the CCK8 assay.
• Cell migration and invasion were evaluated via Transwell assays.
• Apoptosis was analyzed using Annexin V-FITC/PI staining and Western blotting for apoptosis-related proteins (Bcl2, Bax, Caspase-3).
• The PI3K/Akt signaling pathway was examined through Western blot analysis of phosphorylated Akt, mTOR, and p-70.

Main Results:

• UNBS5162 significantly inhibited colon cancer cell proliferation.
• UNBS5162 reduced cell migration and invasion capabilities.
• UNBS5162 markedly induced apoptosis by down-regulating Bcl2, up-regulating Bax, and increasing activated Caspase-3 levels.
• UNBS5162 suppressed the PI3K/Akt pathway, inhibiting Akt and mTOR phosphorylation and reducing p-70 expression.

Conclusions:

• UNBS5162 demonstrates potent anti-cancer activity against colon cancer cells.
• UNBS5162 functions by inducing apoptosis and inhibiting key signaling pathways.
• UNBS5162 represents a promising therapeutic candidate for colon cancer treatment, targeting the PI3K/AKT pathway.